Vitamin E

Pregnancy

The NIH Office of Dietary Supplements lists a pregnancy RDA of 15 mg/day. Its upper limit for supplemental alpha-tocopherol is 800 mg/day at ages 14 to 18 and 1,000 mg/day from age 19; the upper limit is based on possible bleeding effects and is separate from the amount normally obtained from food. MotherToBaby says intake at the RDA and below the upper limit is not expected to increase birth-defect risk, but the human findings it summarizes are mixed. Smedts et al. (2009) studied 276 case mothers and 324 controls in a Dutch case-control study; higher dietary vitamin E and periconceptional supplements alongside a high dietary intake above 14.9 mg/day were associated with congenital heart defects. Shaw et al. (2010) studied 140 d-transposition of the great arteries cases, 163 tetralogy of Fallot cases, and 698 controls; vitamin supplement use was not associated with either defect, while lower dietary vitamin E was associated with d-transposition but not tetralogy of Fallot. Gilboa et al. (2014), using 8,665 cases and 4,525 controls from the US National Birth Defects Prevention Study, found an association between the third intake quartile and all congenital heart defects (OR 1.17, 95% CI 1.01 to 1.35), but the authors noted that selected associations did not show a dose-response pattern of increasing risk with increasing intake. These studies do not establish a consistent dose-response or a separate trimester effect. MotherToBaby says there are no studies suggesting increased miscarriage risk for intakes above the RDA but below the upper limit, and no studies of intake above the upper limit; Boskovic et al. (2005) followed 82 pregnancies exposed to 400 to 1,200 IU/day in the first trimester and found no statistically significant miscarriage difference versus matched controls. This small study does not verify a general absence of risk. For pregnancy outcomes, WHO's 2025 recommendation is against routine combined vitamin E and C supplements to improve maternal and perinatal outcomes, not against ordinary dietary vitamin E. The 2015 Cochrane review included 21 trials with 22,129 women; three trials provided vitamin E alone, but none contributed data, and the analyzed trials tested vitamin E with vitamin C or other agents. In Roberts et al. (2010), 10,154 low-risk nulliparous women were randomized to 1,000 mg vitamin C plus 400 IU vitamin E or placebo; preeclampsia rates were 7.2% and 6.7%, with no significant difference. Newer evidence does not settle the questions. Yang et al. (2025) studied 3,587 pregnancies conceived through assisted reproductive technology; dietary vitamin E was not associated with gestational hypertension or preeclampsia, while supplementation above 100 mg/day in early pregnancy was associated with higher odds (OR 1.68, 95% CI 1.24 to 2.26). Li et al. (2026) studied 10,824 term deliveries in Wuhan and reported an association between serum vitamin E excess and macrosomia (adjusted OR 1.60); this was a biomarker association, not a randomized supplement effect. Carneiro et al. (2026) pooled six trials with 3,823 pregnant participants: supplementation raised maternal alpha-tocopherol, but no consistent clinical benefit was found for gestational age or birth weight. Stunes et al. (2026) studied 57 pregnant people with overweight or obesity and found measured fat-soluble vitamin levels were not associated with birth weight.

Breastfeeding

MotherToBaby says vitamin E is a normal part of breast milk and lists 19 mg/day as the lactation RDA for adults. LactMed's June 2024 review reports that some supplement studies changed milk or infant vitamin E biomarkers. Webb et al. (2009) randomized 626 HIV-infected Tanzanian women to multi-ingredient regimens; milk alpha-tocopherol was higher in multivitamin groups at 3, 6, and 12 months postpartum, but not at delivery. Baylin et al. (2005) randomized 716 HIV-infected mother-infant pairs in Tanzania to vitamin regimens; infant vitamin E serum levels were higher in multivitamin groups at 6 weeks and 6 months. LactMed notes that the contribution of breast milk to those infant levels could not be determined. These studies measured nutrient levels, not clinical infant outcomes; LactMed found no published information on clinical effects in breastfed infants as of its revision date. Prentice (2026) broadly describes vitamin E as an exception among fat-soluble vitamins A, D, and K that can change with maternal diet or high-dose supplementation. Ali et al. (2026) examined 48 breastfeeding women in Ireland at 4 and 8 weeks postpartum; maternal serum and milk alpha-tocopherol were correlated, but the study did not test an isolated vitamin E intervention or infant health outcomes. These findings do not establish a general clinical benefit from higher-dose supplementation.

What was tested

Pregnancy evidence includes case-control studies of dietary intake and supplements, a small prospective high-dose exposure study, randomized trials of combined vitamin C and E supplements, and newer observational studies of supplements or blood levels. Most birth-defect findings are observational and do not establish cause. Breastfeeding evidence includes small studies of milk nutrient levels and infant serum nutrient biomarkers, often in HIV-infected Tanzanian populations and with multi-ingredient supplements. No clinical infant-outcome evidence was identified in the LactMed review.